Back to results
US 12,583,838 B2Granted
Analogs for the treatment of disease
AssigneeInsilico Medicine Hong Kong Limited
InventorsAleksandrs Zavoronkovs, Aleksandr Aliper, Vladimir Aladinskiy, Andrey Kukharenko
Life of this patent
Estimating the term…
Abstract
The disclosure provides TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.
Claims12
A compound represented by Formula (IIA),
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from
- substituted C1-C6 alkyl, wherein the C1-C6 alkyl is substituted with one or more substituents selected from halogen, —OH, —CN, —NO2, —NH2, oxo, ═S, —C1-10 haloalkyl, —O—C1-10 alkyl, —O—C1-6 alkyl-O—C(O)(O—C1-10 alkyl), C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, and 3- to 12-membered heterocycle;
- and
- 3 to 8-membered heterocycle, wherein the 3 to 8-membered heterocycle is optionally substituted with one or more substituents selected from halogen, —OH, —CN, —NO2, —NH2, oxo, ═S, —S(O2)NH2, —C1-10 haloalkyl, —O—C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and optionally substituted C1-10 alkyl, wherein the C1-10 alkyl is optionally substituted with one or more substituents selected from hydroxy, halogen, oxo, —C1-10 haloalkyl, —NH2, —CN, and —NO2;
- R3 is phenyl, which is optionally substituted with one or more substituents selected from halogen, —OH, —CN, —NO2, —NH2, exe, —S, C1-6 alkyl, and —C1-10 haloalkyl;
- and
- R4 is non-halogenated C1-C6 alkyl.
5 more elements
Dependencies are inferred from the claim text.